| 02/19/2026 18:00 |
Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member |
| 02/12/2026 12:00 |
Financial Results - Fiscal Year Ended December 31, 2025 |
| 02/12/2026 12:00 |
Company Presentation |
| 02/12/2026 12:00 |
Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP] |
| 01/26/2026 17:00 |
SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter |
| 01/19/2026 13:30 |
The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS |
| 01/05/2026 08:00 |
Upgrading the Drug Discovery Platform ibVIS to aibVIS |
| 12/22/2025 15:30 |
Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline |
| 12/15/2025 17:00 |
Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio" |
| 12/15/2025 17:00 |
Company Presentation |
| 11/17/2025 15:30 |
Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction |
| 11/11/2025 16:00 |
Organizational Reforms and Personnel Changes |
| 11/11/2025 16:00 |
[Summary] Financial Results for the Nine Months |
| 11/11/2025 16:00 |
Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP] |
| 11/04/2025 15:30 |
Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic |
| 10/14/2025 17:00 |
Revised Financial Forecast for FY2025 |
| 09/29/2025 12:00 |
Relocation of the Shin-Kawasaki Research Institute |
| 09/24/2025 15:30 |
The Jikei University School of Medicine and VIS announce Start of Joint Research for Fundamentally Enhancing Therapeutic Effects of Pharmaceuticals |
| 09/16/2025 12:00 |
Nomination of a Candidate for Independent Outside Director |
| 08/04/2025 16:00 |
Non-consolidated Financial Results for the Six Months Ended June 30, 2025 [Under Japanese GAAP] |
| 08/04/2025 16:00 |
Financial Results - Fiscal Year Ended December 31, 2025, 2nd Quarter |
| 07/28/2025 16:00 |
Patent owned by Veritas In Silico receives Notice of Allowance in the U.S. |
| 07/03/2025 15:30 |
Mitsubishi Gas Chemical and VIS Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs |
| 06/16/2025 16:30 |
Determination of Target Disease for mRNA-Targeted Nucleic Acid Drug for In-house Pipeline |
| 05/23/2025 13:00 |
Shionogi and Veritas In Silico Announce Milestone Achievement in Joint Drug Discovery Research of mRNA-targeted Small Molecules |
| 05/09/2025 16:00 |
Financial Results - Fiscal Year Ended December 31,2025, 1st Quarter |
| 05/09/2025 16:00 |
Non-consolidated Financial Results for the Three Months Ended March 31,2025 [Under Japanese GAAP] |
| 02/20/2025 17:00 |
Organizational Reforms and Personnel Changes |
| 02/20/2025 17:00 |
Appointing Candidates for Director and Alternate Audit & Supervisory Board Member |
| 02/20/2025 17:00 |
Reduction of Capital Stock (Capital Reduction) |
